Side Effects of DSIP and Retatrutide
DSIP (delta-sleep-inducing peptide) has demonstrated minimal to no side effects in human studies, while retatrutide causes predominantly gastrointestinal side effects similar to other GLP-1 receptor agonists.
DSIP Side Effects
Clinical Safety Profile
DSIP has shown a remarkably benign safety profile across multiple human studies. No psychologic, physiologic, or biochemical side effects were observed in controlled trials 1. The peptide was well-tolerated even with repeated administration over 7 consecutive nights in chronic insomniacs 2.
Key Safety Findings:
- No sedation in the classic pharmacologic sense - despite promoting sleep, DSIP does not cause daytime drowsiness or impaired alertness 3, 1
- No hormonal disruption - does not affect ACTH or cortisol secretion 4
- Improved daytime function - actually increased alertness and performance during waking hours 2
- Minimal arousal effect - only a slight arousing effect noted in the first hour after injection, followed by sleep-promoting effects 3
Important Caveat:
The FDA drug label 5 appears to reference diphenhydramine (an antihistamine), NOT the research peptide DSIP. This is a labeling confusion - the warnings about drowsiness, avoiding alcohol, and contraindications for children under 12 apply to over-the-counter sleep aids containing diphenhydramine, not to the investigational peptide DSIP used in research studies.
Retatrutide Side Effects
Common Gastrointestinal Effects
Retatrutide causes the same side effect profile as other GLP-1 receptor agonists, primarily gastrointestinal in nature 6:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Esophageal reflux
- Fecal urgency
Serious Safety Concerns
Thyroid C-cell tumor risk: Demonstrated in rodents, though human relevance remains undetermined. Contraindicated in patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 6.
Pancreatitis: Reported in clinical trials; discontinue immediately if suspected 6.
Acute kidney injury risk: Use caution when initiating or escalating doses in patients with kidney disease due to dehydration from gastrointestinal side effects 6.
Gallbladder complications: May cause cholelithiasis and gallstone-related complications 6.
Contraceptive interactions: May reduce efficacy of oral hormonal contraceptives due to delayed gastric emptying. Patients should switch to non-oral contraceptive methods or add barrier contraception for 4 weeks after initiation and 4 weeks after each dose escalation 6.
Metabolic Concerns
Malnutrition and sarcopenia risk: Incretin therapies may increase risk, particularly with significant weight loss (>20%) or rapid weight loss (>4 kg/month). Encourage resistance training and adequate protein intake 6.
Additional Side Effects
- Nasopharyngitis
- Headache
- Injection site reactions (as with other injectable medications)
Monitoring Requirements
- Screen for acute kidney injury when initiating or increasing doses, especially in patients with pre-existing kidney disease
- Monitor for signs of pancreatitis
- Assess for gallbladder disease
- Evaluate for malnutrition with significant weight loss